Branded drugs go generic, making what we pay for them more of a mortgage-like investment than a rent-like expense. Although some health economists recognize that value, hardly any cost-effectiveness models have taken it into account. We’re working with leading academic health economists to redo old math to see how much value has been overlooked.
Feel free to reach out with questions, concerns, or comments.
Contact us
